Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40W1C | ISIN: US2936025046 | Ticker-Symbol:
NASDAQ
27.06.25 | 20:43
2,210 US-Dollar
-0,45 % -0,010
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ENSYSCE BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
ENSYSCE BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur ENSYSCE BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiEnsysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2133~ Treatment to Evaluate Effect of Food on Overdose Protection of MPAR ~~ Grant Funds from NIDA Accelerating Clinical Development Program ~ SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 24, 2025 / Ensysce...
► Artikel lesen
11.06.Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025154~ Pain Management, RE-Invented: A New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical...
► Artikel lesen
05.06.Ensysce Biosciences ernennt Baker Tilly zum neuen Wirtschaftsprüfer1
05.06.Ensysce Biosciences, Inc. - 8-K, Current Report3
04.06.Ensysce Flat on Receiving Grant-
04.06.Ensysce Biosciences sichert sich zusätzliche 5,3 Millionen US-Dollar NIDA-Förderung2
ENSYSCE BIOSCIENCES Aktie jetzt für 0€ handeln
04.06.Ensysce Biosciences secures additional $5.3M NIDA grant3
04.06.Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection184~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~~ Funds Accelerate Path Towards Commercialization ~ SAN DIEGO, CA / ACCESS Newswire / June 4, 2025 / Ensysce Biosciences...
► Artikel lesen
13.05.Ensysce Biosciences Reports First Quarter 2025 Financial Results291Receives U.S. Patent for Groundbreaking Treatment for Opioid Use DisorderClinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / ACCESS Newswire / May 13, 2025...
► Artikel lesen
13.05.Ensysce Biosciences, Inc. - 10-Q, Quarterly Report2
12.05.Ensysce Biosciences Bolsters Management Team with Regulatory Expert191~ Advanced Preparation for New Drug Application ~ SAN DIEGO, CA / ACCESS Newswire / May 12, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical...
► Artikel lesen
02.05.Ensysce Biosciences, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
24.04.Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds277SAN DIEGO, CA / ACCESS Newswire / April 24, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief...
► Artikel lesen
24.04.Pre-market Movers: Linkage Global, Cantor Equity Partners, Impinj, Robert Half, Ensysce Biosciences703DALLAS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.50 A.M. ET).In the Green Linkage Global Inc (LGCB) is up over 24% at $2.37. Cantor...
► Artikel lesen
23.04.Ensysce Biosciences announces exercise of warrants for $2.2M gross proceeds1
23.04.Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why1
23.04.Ensysce Biosciences to raise $2.2 million through warrant exercise1
23.04.Ensysce Biosciences sammelt 2,2 Millionen US-Dollar durch Optionsscheinausübung-
23.04.Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds288SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief...
► Artikel lesen
23.04.Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder173~ Applies TAAP and MPAR Technology to Produce Novel OUD Treatments ~~ Prioritizes Safety and Tolerability for OUD Patients ~ SAN DIEGO, CA / ACCESS Newswire / April 23, 2025 / Ensysce Biosciences, Inc....
► Artikel lesen
Weiter >>
54 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1